...
首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells
【24h】

NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells

机译:NIK控制经典和替代性NF-κB激活,对于人类T细胞淋巴瘤细胞的存活是必不可少的

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: Peripheral T-cell lymphomas (PTCL) are a heterogeneous entity of neoplasms with poor prognosis, a lack of effective therapies, and a largely unknown molecular pathology. Deregulated NF-κB activity has been associated with several lymphoproliferative diseases, but its importance in T-cell lymphomagenesis is poorly understood. We investigated the function of the NF-κB-inducing kinase (NIK), in this pathway and its role as a potential molecular target in T-cell lymphomas. Experimental Design: We used immunohistochemistry to analyze the expression of different NF-κB members in primary human PTCL samples and to study its clinical impact. With the aim of inhibiting the pathway, we used genetic silencing of NIK in several T-cell lymphoma cell lines and observed its effect on downstream targets and cell viability. Results: We showed that the NF-κB pathway was activated in a subset of PTCLs associated with poor overall survival. NIK was overexpressed in a number of PTCL cell lines and primary samples, and a pivotal role for NIK in the survival of these tumor cells was unveiled. NIK depletion led to a dramatic induction of apoptosis in NIK-overexpressing cell lines and also showed a more pronounced effect on cell survival than inhibitor of kappa B kinase (IKK) knockdown. NIK silencing induced a blockage of both classical and alternative NF-κB activation and reduced expression of several prosurvival and antiapoptotic factors. Conclusions: The results of the present study indicate that NIK could be a promising therapeutic target in these aggressive malignancies.
机译:目的:外周T细胞淋巴瘤(PTCL)是肿瘤的异质实体,预后较差,缺乏有效的治疗方法以及分子病理学广为人知。失调的NF-κB活性与几种淋巴增生性疾病有关,但人们对其在T细胞淋巴瘤发生中的重要性了解甚少。我们调查了NF-κB诱导激酶(NIK)在此途径中的功能及其作为T细胞淋巴瘤中潜在的分子靶标的作用。实验设计:我们使用免疫组化分析了原发性人PTCL样品中不同NF-κB成员的表达,并研究了其临床影响。为了抑制该途径,我们在几种T细胞淋巴瘤细胞系中使用了NIK的基因沉默,并观察了其对下游靶标和细胞活力的影响。结果:我们显示NF-κB通路在PTCLs的一个子集中被激活,与总体生存期差有关。 NIK在许多PTCL细胞系和原代样品中过表达,并且揭示了NIK在这些肿瘤细胞存活中的关键作用。 NIK耗竭导致过表达NIK的细胞系发生凋亡的显着诱导,并且比kappa B激酶(IKK)抑制因子对细胞存活的影响更明显。 NIK沉默导致经典和替代性NF-κB激活受阻,并降低了几种存活和抗凋亡因子的表达。结论:本研究结果表明,NIK在这些侵袭性恶性肿瘤中可能是有希望的治疗靶标。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号